PET Scan (FDG-PET/CT): Cancer Staging, PSMA PET & Amyloid PET — Cost, Top Hospitals & Success Rates | MyMedicPlus

Positron emission tomography (PET) is a functional nuclear medicine imaging technique that maps metabolic activity in living tissue, rather than depicting anatomy alone. In clinical practice, PET is almost always performed as a hybrid PET/CT scan, combining the metabolic information of PET with the precise anatomical localisation of computed tomography in a single imaging session. This fusion is essential for correctly attributing areas of increased tracer uptake to specific organs, lymph nodes, or lesions.

The most widely used radiotracer is 18F-fluorodeoxyglucose (FDG) — a radiolabelled glucose analogue that is taken up by metabolically active cells in proportion to their glucose consumption. Malignant tumours, inflammatory foci, and active infection all demonstrate elevated FDG uptake relative to surrounding normal tissue. The 18F isotope decays by emitting a positron, which annihilates with a nearby electron to produce two 511 keV gamma rays travelling in exactly opposite directions; the PET camera detects these coincident photons and reconstructs a 3D image of tracer distribution.

Quantitative analysis uses the Standardised Uptake Value (SUVmax) — the maximum tracer concentration in a region of interest normalised to injected dose and patient body weight. An SUVmax >2.5 in a pulmonary nodule, for example, is associated with a high probability of malignancy, though these thresholds vary by tumour type and organ. Modern PET/CT scanners (including digital silicon photomultiplier systems) offer improved spatial resolution (~3 mm) and reduced scan times compared to earlier generation equipment. Dedicated PET/MRI systems provide superior soft-tissue contrast for brain, pelvic, and paediatric applications.

PET scanning is a versatile diagnostic tool used across oncology, cardiology, and neurology. Its primary clinical value lies in detecting disease at the molecular level, often before anatomical changes are visible on CT or MRI:

• Oncology — cancer staging and response assessment: FDG-PET/CT is standard of care for staging and restaging lung cancer, lymphoma (Hodgkin and non-Hodgkin), head and neck squamous cell carcinoma, colorectal cancer, breast cancer, cervical cancer, oesophageal cancer, and melanoma. It detects nodal and distant metastases with sensitivity and specificity superior to CT alone in most tumour types.
• Lymphoma response assessment (Deauville Score): The Deauville 5-point scale compares residual FDG uptake in a treated lymphoma mass against reference background structures (mediastinal blood pool and liver). Scores 1–2 indicate complete metabolic response; score 3 indicates probable response; scores 4–5 indicate inadequate response or progression, prompting treatment escalation. This score is validated by international lymphoma trials and supersedes CT-based RECIST criteria for lymphoma response.
• PERCIST response criteria: The PET Response Criteria in Solid Tumours (PERCIST) framework uses SUL (lean body mass-normalised SUV) to standardise metabolic response assessment for solid cancers across institutions, complementing or replacing anatomical RECIST criteria.
• 68Ga-PSMA PET for prostate cancer: Prostate-specific membrane antigen (PSMA) PET using 68Ga or 18F-PSMA radiotracers has transformed prostate cancer restaging, detecting recurrence sites at PSA values as low as 0.2–0.5 ng/mL — far earlier than conventional bone scan or CT — and directing salvage radiotherapy or surgery.
• Amyloid and tau PET (neurology): 18F-florbetapir, florbetaben, or flutemetamol PET scans detect cortical amyloid-beta plaques in Alzheimer's disease, distinguishing it from other dementias. 18F-flortaucipir (AV-1451) images tau neurofibrillary tangles. These scans are used for atypical or early-onset dementia diagnosis and are required for eligibility assessment for anti-amyloid therapies.
• Cardiac viability (hibernating myocardium): FDG cardiac PET identifies viable but dysfunctional myocardium (hibernating myocardium) in patients with ischaemic cardiomyopathy by demonstrating preserved glucose metabolism in regions with reduced perfusion. This metabolic-perfusion mismatch pattern predicts functional recovery after coronary revascularisation.

PET scanning is prescribed by oncologists, cardiologists, neurologists, or nuclear medicine physicians after consideration of clinical indication, contraindications, and the availability of alternative imaging:

• Oncological indications: Patients newly diagnosed with cancer where staging will change management; patients with suspected or confirmed disease recurrence after treatment; monitoring of response to chemotherapy or radiotherapy (typically performed after 2–3 cycles) using standardised protocols.
• Neurological indications: Patients with atypical or early-onset dementia where FDG-PET hypometabolism patterns (bitemporal-parietal in Alzheimer's; frontotemporal in FTD) or amyloid PET imaging can resolve diagnostic uncertainty. Amyloid PET is now required for anti-amyloid therapy eligibility under FDA-approved protocols.
• Cardiac indications: Patients with severely impaired left ventricular ejection fraction (EF <35%) and multivessel coronary artery disease being evaluated for high-risk revascularisation; viability PET identifies which myocardial territories will functionally recover after bypass or PCI.
• Absolute contraindications: Pregnancy is the only absolute contraindication to FDG-PET/CT due to foetal radiation exposure. Breastfeeding mothers should pause feeds for 12–24 hours after FDG injection.
• Relative considerations: Poorly controlled diabetes (blood glucose >11 mmol/L) significantly impairs FDG tumour uptake (competing glucose reduces tumour-to-background ratios) and is a contraindication to scanning that day. Oral antidiabetic medications should be omitted on the morning of the scan; insulin adjustments require specialist guidance. Severe claustrophobia may require anxiolytic premedication. Patients unable to lie still for 20–30 minutes may need sedation.
• Paediatric use: PET/MRI is preferred over PET/CT in children to reduce radiation dose from CT. Dedicated weight-based tracer dosing protocols are used.

Referral is most appropriate when the metabolic information from PET will meaningfully change clinical management — not as a routine surveillance tool where anatomical imaging or tumour markers suffice.

PET imaging has expanded far beyond FDG to include disease-specific radiotracers that target particular receptor systems, biochemical pathways, or molecular markers:

• 18F-FDG PET/CT (standard): Exploits the Warburg effect — malignant cells' preferential glycolysis even under normoxic conditions. Remains the workhorse tracer for most oncological indications. Standard protocol: 6-hour fast, intravenous injection of 3–5 MBq/kg FDG, 40–60 minute uptake period in a quiet, warm room (to suppress brown adipose tissue uptake), followed by 15–25 minute whole-body acquisition from skull base to mid-thigh. Concurrent CT provides anatomical co-registration and enables attenuation correction.
• 68Ga-PSMA PET/CT (prostate cancer): 68Ga-PSMA-11 and 18F-PSMA-1007 target the prostate-specific membrane antigen overexpressed on prostate cancer cells. Detects recurrent disease at PSA <0.5 ng/mL post-radical prostatectomy with sensitivity approaching 85–90% — approximately 3-fold better than conventional imaging. Also used for initial staging in high-risk disease and for dosimetry before 177Lu-PSMA radioligand therapy.
• 68Ga-DOTATATE PET/CT (neuroendocrine tumours): Gallium-labelled somatostatin analogue with exceptional affinity for somatostatin receptor subtype 2 (SSTR2), overexpressed on well-differentiated neuroendocrine tumours (NETs). Superior to Octreoscan SPECT and CT for NET staging and detection of occult primaries.
• Amyloid PET (18F-florbetapir, florbetaben, flutemetamol): Detects cortical fibrillar amyloid-beta burden. A positive scan (cortical grey matter retention greater than white matter) confirms amyloid pathology, supporting Alzheimer's disease diagnosis. Now mandated for access to FDA-approved anti-amyloid immunotherapies (lecanemab, donanemab).
• Tau PET (18F-flortaucipir): Maps neurofibrillary tau tangles — the second core pathological feature of Alzheimer's disease. Tau PET shows stronger correlation with clinical symptom severity and cognitive stage than amyloid PET, and is an emerging biomarker for disease staging and clinical trial enrolment.
• Cardiac FDG viability PET: Requires high-carbohydrate preparation or insulin clamp protocol to ensure cardiac glucose metabolism. Perfusion agent (13N-ammonia or 82Rb) is combined with FDG metabolic imaging to identify mismatch patterns indicating hibernating myocardium. Sensitivity for viability detection: ~90%.

PET scanning offers unique diagnostic advantages that anatomical imaging modalities (CT, MRI) alone cannot provide:

• Early detection of occult disease: FDG-PET detects lymph node metastases and distant organ deposits before they reach the size threshold for CT detection (typically <10 mm). In lung cancer staging, PET/CT upstages disease (revealing previously unsuspected distant metastases) in 20–30% of cases compared to CT alone, fundamentally changing the treatment intent.
• Single whole-body examination: A single FDG-PET/CT scan covers the entire body from skull to mid-thigh, providing simultaneous primary tumour characterisation, nodal staging, and distant metastasis detection that would otherwise require multiple separate CT or bone scans.
• Metabolic response assessment: PET measures tumour viability and metabolic activity — not just size. Anatomical response by CT (RECIST) can lag weeks or months behind true treatment effect; PET can demonstrate metabolic "complete response" in a mass that remains anatomically enlarged due to residual fibrosis, avoiding unnecessary additional therapy.
• Treatment decision support: PET findings change clinical management in 25–35% of cancer patients. Upstaging from localised to metastatic disease avoids futile curative-intent surgery; downstaging by excluding suspected metastases confirms suitability for radical treatment. This impact justifies the scan cost in most oncological contexts.
• Prostate cancer recurrence localisation: 68Ga-PSMA PET detects recurrence sites in men with rising PSA after radical prostatectomy or radiotherapy, enabling targeted salvage radiotherapy with curative intent rather than empirical hormonal therapy — outcomes from the ProPSMA randomised trial confirm significantly better management decisions with PSMA PET versus conventional imaging.
• Dementia differential diagnosis: FDG-PET metabolic pattern recognition and amyloid PET provide high diagnostic accuracy for Alzheimer's (85–90% sensitivity and specificity), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and vascular dementia — substantially improving on clinical diagnosis alone.

PET scanning is a safe diagnostic procedure, but patients should understand its radiation exposure profile, limitations, and the implications of false-positive findings:

• Radiation exposure: A standard whole-body FDG-PET/CT scan delivers approximately 7 mSv effective dose from FDG (positron decay) plus 6–10 mSv from the CT component — a combined effective dose of approximately 14–17 mSv. This is roughly equivalent to 5–7 years of average background radiation. The risk from a single scan is very low (estimated additional lifetime cancer risk <0.1%), but multiple repeat PET/CT scans in younger patients require cumulative dose tracking and clinical justification.
• False-positive findings: FDG is taken up by any highly metabolically active tissue — not only cancer. Active infection (tuberculosis, fungal infections), sarcoidosis, post-surgical inflammation, and brown adipose tissue (periscapular fat in cold conditions) all cause elevated FDG uptake that can mimic malignancy. These findings require clinical correlation and, often, tissue biopsy for definitive characterisation.
• False-negative results: Poorly controlled diabetes, recent chemotherapy (glucose transporter downregulation), very small lesions (<5–6 mm, below scanner spatial resolution), and low-FDG-avid tumours (prostate adenocarcinoma, well-differentiated thyroid cancers, mucinous tumours, hepatocellular carcinoma in some settings) can yield false-negative FDG-PET scans.
• Injection site reactions: Intravenous FDG injection is generally well tolerated. Rare hypersensitivity reactions to the tracer or its excipients are reported in <0.1% of administrations.
• Contrast medium risks: Many PET/CT protocols use intravenous iodinated CT contrast to improve anatomical characterisation; standard CT contrast risks of nephrotoxicity (in pre-existing renal impairment) and anaphylaxis apply.
• Claustrophobia and patient discomfort: The PET/CT gantry bore is wider than MRI, so claustrophobia is uncommon. However, patients must remain still for 20–30 minutes during acquisition; movement artifact degrades image quality. The scan room temperature is kept cool to reduce brown fat FDG uptake, which some patients find uncomfortable.

Pregnant patients should not undergo FDG-PET/CT unless the clinical benefit in a life-threatening situation unambiguously outweighs the radiation risk to the foetus.

PET scan results are interpreted by a nuclear medicine physician or radiologist specialised in PET imaging and reported in the clinical context of the patient's diagnosis, treatment history, and concurrent medications:

• SUVmax interpretation: The maximum standardised uptake value (SUVmax) quantifies peak tracer concentration normalised to body weight and injected dose. While SUVmax >2.5 is frequently cited as a malignancy threshold for pulmonary nodules, cut-off values are tumour-specific and site-specific — they should never be interpreted in isolation without clinical context. SUV can be inflated by hyperglycaemia, partial volume effects, and scanner calibration differences between institutions.
• Deauville score (lymphoma): The 5-point Deauville scale is the international standard for end-of-treatment and interim PET assessment in Hodgkin and aggressive non-Hodgkin lymphoma. A Deauville score of 1–2 represents complete metabolic response; 3 indicates minimal residual uptake that is typically managed conservatively; 4–5 indicates residual metabolic disease requiring biopsy, additional staging, and treatment escalation.
• PERCIST criteria: PET Response Criteria in Solid Tumours (PERCIST 1.0) defines complete metabolic response (CMR), partial metabolic response (>30% SUL decline), stable metabolic disease, and progressive metabolic disease for serial FDG-PET comparison in solid tumours. PERCIST is complementary to but distinct from anatomical RECIST criteria used in CT-based response assessment.
• Post-treatment inflammation: FDG-PET performed too soon after completing chemotherapy or radiotherapy may show elevated uptake at the treatment site due to therapy-induced inflammation — a "flare" phenomenon. Scanning is optimally deferred to 6–8 weeks after last chemotherapy and 3 months after radiotherapy completion to minimise inflammatory false positives.
• Subsequent imaging schedule: In lymphoma, interim PET after 2–4 cycles and end-of-treatment PET are standard. In solid tumours, scheduling is disease and protocol-specific. Follow-up scans should be planned in advance to standardise uptake time, scanner parameters, and patient preparation, enabling valid serial comparison.
• Multidisciplinary team (MDT) review: PET findings should always be reviewed within the context of a multidisciplinary oncology, cardiology, or neurology team meeting before any major treatment decision is made based on imaging alone.

PET scan cost varies substantially by country, tracer type, clinical indication, and whether the scan is state-funded, insurance-covered, or self-pay:

• United States: FDG-PET/CT costs USD 2,500–4,500 at major cancer centres and private hospitals. With insurance coverage (Medicare and most commercial plans cover oncological indications), patient out-of-pocket costs typically range from USD 200–800 depending on the plan. PSMA PET costs USD 3,000–5,000 and coverage varies by payer and PSA threshold criteria.
• Western Europe: NHS-funded PET/CT in the UK incurs no patient cost for approved oncological or neurological indications. In France, Germany, and the Netherlands, PET/CT is fully reimbursed through statutory insurance systems. Private or self-pay scans cost EUR 1,200–3,000.
• India: FDG-PET/CT costs INR 12,000–25,000 (USD 150–300) at government facilities and INR 18,000–45,000 (USD 220–550) at private hospitals including AIIMS, Tata Memorial, and Apollo Hospitals — representing 5–10% of US cost for equivalent technology.
• Southeast Asia: Thailand (Bumrungrad, BNH Hospital, Samitivej): USD 400–800. Singapore (National Cancer Centre, Mount Elizabeth): USD 1,500–2,500. Malaysia (Pantai, Gleneagles): USD 600–1,200.
• Tracer-specific costs: 68Ga-PSMA PET adds USD 800–1,500 to base PET/CT costs in the USA due to on-site generator production or commercial supply. Amyloid PET (18F-florbetapir) costs USD 3,000–4,000 for tracer alone in the USA. In countries with cyclotron production, tracer costs are lower.
• Repeat scans for monitoring: Patients undergoing serial response assessment (e.g., lymphoma patients with interim and end-of-treatment PET) will incur costs for 2–4 scans during a treatment course. Annual surveillance PET in specific cancer types adds to cumulative cost.
• Insurance and prior authorisation: In the USA, prior authorisation is required for most PET scans. Approved indications include most solid tumours for initial staging, restaging, and response assessment. Amyloid PET coverage requires documentation of diagnostic uncertainty criteria and specialist involvement.

Several imaging modalities provide complementary or partially overlapping diagnostic information; choice depends on the clinical question, available technology, radiation tolerance, and cost:

• CT scanning (contrast-enhanced): Standard CT remains the primary modality for anatomical staging of most cancers. It is lower cost, more widely available, and faster than PET/CT. However, CT cannot distinguish viable tumour from necrosis, fibrosis, or inflammatory change in treated lesions — the key limitation that PET/CT addresses. CT is complementary to PET, not a true alternative for metabolic disease assessment.
• MRI (with or without gadolinium contrast): MRI provides superior soft-tissue contrast, particularly for brain, liver, pelvic, and musculoskeletal lesions. It avoids ionising radiation. Diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) can assess tumour cellularity and vascularity. However, MRI lacks the whole-body coverage and functional metabolic information of FDG-PET/CT. Whole-body MRI with DWI is an emerging radiation-free alternative for metastatic staging in selected cancers (myeloma, prostate, breast).
• SPECT/CT (single-photon emission CT): Nuclear medicine bone scan (99mTc-methylene diphosphonate) plus SPECT/CT remains widely used for bone metastasis detection where PET/CT is not available. Octreoscan SPECT for neuroendocrine tumours has been largely superseded by 68Ga-DOTATATE PET/CT due to superior sensitivity and resolution. 99mTc-MIBI cardiac perfusion SPECT is an alternative to cardiac PET viability where PET is unavailable.
• Tumour markers: PSA, CA-125, CEA, AFP, and chromogranin A provide cost-effective biochemical monitoring of specific cancers but cannot localise disease sites or distinguish local recurrence from distant metastasis — the information PET uniquely provides.
• Bone scintigraphy: Whole-body 99mTc bone scan is widely used for bone metastasis surveillance in breast and prostate cancer. It is substantially cheaper than PET but has lower specificity (degenerative disease, fractures, and inflammatory conditions all cause false-positive uptake) and lower sensitivity for purely lytic metastases than FDG or PSMA PET.
• Liquid biopsy and circulating tumour DNA (ctDNA): Plasma ctDNA analysis is an emerging non-imaging alternative for treatment response monitoring, detecting molecular residual disease, and identifying resistance mutations — with the advantage of complete absence of radiation exposure. However, ctDNA cannot localise individual disease sites or guide focal treatments.

The optimal imaging strategy is determined at the multidisciplinary team meeting based on the specific clinical question, available technology at the treating institution, patient fitness for contrast agents or radiation, and cost-effectiveness in the local healthcare system.